Strong first half at Clinigen marred by one-off hit to cash
Specialist pharma services group Clinigen (CLIN:AIM) reported interim gross profits up 35% to £108m, driven by acquisitions. Underlying sales growth of 9% was at the top end of guidance of 5%-to-10%), yet the shares softened 4.4% to...
25 February 2020
